IMPROVING VISION OUTCOMES THROUGH INNOVATION: COMPARING CLINICAL, HEALTHCARE SYSTEM AND PATIENT-RELEVANT OUTCOMES IN CATARACT SURGERY
Author(s)
Alissa J Brown, MPH1, Hansoo Kim, BSc, MSc, PhD2.
1BOND UNIVERSITY, Gold Coast, Australia, 2Bond University, Robina, Australia.
1BOND UNIVERSITY, Gold Coast, Australia, 2Bond University, Robina, Australia.
OBJECTIVES: Cataract is a leading cause of vision loss, reducing quality of life and independence. Falls risk is significantly elevated in people with age-related cataract-related vision loss (OR=2.87, 95% CI=1.78-4.67). With almost 100 million people globally living with cataract-related vision impairment and the WHO estimating 1 in 2 who need surgery cannot access it, access to effective and innovative solutions to address this unmet need is critical. Replacing the natural lens with an intraocular lens (IOL) is safe, durable, and effective. The Light Adjustable Lens (LAL) uniquely customises post-operative vision, removing reliance on pre-operative biometric prediction.
METHODS: This study compared two clinically and patient-relevant outcomes from the pivotal registration trial: Uncorrected visual acuity (UCVA), vision without spectacles or contact lenses, and Best spectacle-corrected visual acuity (BSCVA), vision with correction, measured as the percent achieving 20/20 or better the baseline measure for normal vision, at 6 months. Data from 600 eyes randomized to implantation with LAL (n=403) or monofocal IOL (n=197) were analysed.
RESULTS: The rates of UCVA of 20/20 or better were 70.1% (274/391) for LAL and 36.3% (70/193) for monofocal IOL groups, a statistically significant difference of 33.8%, p<0.0001, more patients implanted with the LAL achieving a UCVA of 20/20. The rates of BSCVA of 20/20, baseline for normal vision, at 6 months were higher with LAL, 94.4% (369/391), versus with monofocal IOLs, 82.9% (160/193), although statistical significance was not reached.
CONCLUSIONS: The LAL significantly improved uncorrected visual acuity, vision without dependence on spectacles or contact lenses, compared to the most widely used standard of care, monofocal IOLs. The broader value of innovative IOLs, to improved visual acuity and the downstream benefits such as vision aid independence, to patients, clinicians, healthcare (formal and informal), social services and productivity should inform decisions about adoption and access.
METHODS: This study compared two clinically and patient-relevant outcomes from the pivotal registration trial: Uncorrected visual acuity (UCVA), vision without spectacles or contact lenses, and Best spectacle-corrected visual acuity (BSCVA), vision with correction, measured as the percent achieving 20/20 or better the baseline measure for normal vision, at 6 months. Data from 600 eyes randomized to implantation with LAL (n=403) or monofocal IOL (n=197) were analysed.
RESULTS: The rates of UCVA of 20/20 or better were 70.1% (274/391) for LAL and 36.3% (70/193) for monofocal IOL groups, a statistically significant difference of 33.8%, p<0.0001, more patients implanted with the LAL achieving a UCVA of 20/20. The rates of BSCVA of 20/20, baseline for normal vision, at 6 months were higher with LAL, 94.4% (369/391), versus with monofocal IOLs, 82.9% (160/193), although statistical significance was not reached.
CONCLUSIONS: The LAL significantly improved uncorrected visual acuity, vision without dependence on spectacles or contact lenses, compared to the most widely used standard of care, monofocal IOLs. The broader value of innovative IOLs, to improved visual acuity and the downstream benefits such as vision aid independence, to patients, clinicians, healthcare (formal and informal), social services and productivity should inform decisions about adoption and access.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
MT2
Topic
Medical Technologies
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)